NASDAQ:ALLO

Allogene Therapeutics (ALLO) Stock Forecast, Price & News

$3.65

-0.07 (-1.88%)

(As of 09/22/2023 ET)

Compare

Today's Range: $3.63
▼
$3.81
50-Day Range: $3.65
▼
$5.41
52-Week Range: $3.63
▼
$12.21

Volume: 1.51 million shs
Average Volume: 1.60 million shs
Market Capitalization: $611.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.35

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.64 Rating Score
Upside/Downside: 347.8% Upside
$16.35 Price Target
Short Interest: Bearish
30.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 2 Articles This Week
Insider Trading: Selling Shares
$42,900 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.25) to ($2.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

471st out of 965 stocks

Biological Products, Except Diagnostic Industry

73rd out of 160 stocks

3.3

Analyst's Opinion

Consensus Rating
Allogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $16.35, Allogene Therapeutics has a forecasted upside of 347.8% from its current price of $3.65.
Amount of Analyst Coverage
Allogene Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
30.26% of the float of Allogene Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Allogene Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Allogene Therapeutics has recently decreased by 2.01%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Allogene Therapeutics does not currently pay a dividend.
Dividend Growth
Allogene Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALLO.

1.4

News and Social Media Coverage

News Sentiment
Allogene Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,900.00 in company stock.
Percentage Held by Insiders
27.40% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.51% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allogene Therapeutics are expected to grow in the coming year, from ($2.25) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allogene Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allogene Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allogene Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Price History

30 days | 90 days | 365 days | Advanced Chart

ALLO Stock News Headlines

September 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Enanta Pharmaceuticals (ENTA) and ADC Therapeutics (ADCT)

September 1, 2023 | insidermonkey.com

5 Best High Risk High Reward Stocks To Buy Now

September 24, 2023 | Altimetry (Ad)

Biden's latest bailout--terrible for America?

And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—

August 29, 2023 | finance.yahoo.com

16 Most Shorted Stocks Right Now

August 15, 2023 | markets.businessinsider.com

William Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX)

August 14, 2023 | markets.businessinsider.com

William Blair Sticks to Its Hold Rating for Century Therapeutics (IPSC)

August 14, 2023 | finance.yahoo.com

Allogene Therapeutics Appoints Earl Douglas as General Counsel

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Athira Pharma (ATHA) and Adicet Bio (ACET)

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

August 7, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

August 7, 2023 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

August 4, 2023 | markets.businessinsider.com

Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital

August 4, 2023 | msn.com

Oppenheimer Reiterates Allogene Therapeutics (ALLO) Outperform Recommendation

August 3, 2023 | finance.yahoo.com

Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss

August 2, 2023 | finance.yahoo.com

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

July 28, 2023 | cnbc.com

These are the most heavily shorted stocks right now

July 26, 2023 | seekingalpha.com

Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before

July 26, 2023 | finance.yahoo.com

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

July 12, 2023 | benzinga.com

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

July 6, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX)

July 3, 2023 | benzinga.com

Short Volatility Alert: Allogene Therapeutics

June 28, 2023 | markets.businessinsider.com

Positive Report for Black Diamond Therapeutics (BDTX) from H.C. Wainwright

June 20, 2023 | benzinga.com

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target

June 16, 2023 | benzinga.com

Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status

June 16, 2023 | markets.businessinsider.com

Analyst Ratings for Allogene Therapeutics

June 16, 2023 | fool.com

Allogene Therapeutics (NASDAQ: ALLO)

June 15, 2023 | finance.yahoo.com

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

See More Headlines

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings: 8/02/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLO
CUSIP: N/A
CIK: 1737287
Web: www.allogene.com
Phone: (650) 457-2700
Fax: N/A
Employees: 359
Year Founded: 2018

Price Target and Rating

Average Stock Price Forecast: $16.35
High Stock Price Forecast: $31.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +347.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.64
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-332,630,000.00
Net Margins: -184,733.34%
Pretax Margin: -184,733.33%
Return on Equity: -54.13%
Return on Assets: -44.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.18
Quick Ratio: 9.18

Sales & Book Value

Annual Sales: $240,000.00
Price / Sales: 2,549.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.62 per share
Price / Book: 0.79

Miscellaneous

Outstanding Shares: 167,630,000
Free Float: 121,696,000
Market Cap: $611.85 million
Optionable: Not Optionable
Beta: 0.77

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Arie S. Belldegrun F.A.C.S. (Age 74)
FACS, M.D., Co-Founder & Exec. Chairman
Comp: $714.25k

Dr. David D. Chang M.D. (Age 63)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $1.1M

Mr. Joshua A. Kazam (Age 46)
Co-Founder & Director
Comp: $711k

Yinlin Chen
Sr. VP of Fin.

Mr. Timothy L. Moore Ph.D. (Age 62)
Exec. VP & Chief Technical Officer

Ms. Barbra Sasu
Chief Scientific Officer

Mr. Stephen Cheng
Chief Information Officer

Mr. Earl M. Douglas Esq. (Age 60)
Gen. Counsel & Compliance Officer

Ms. Susan R. Lundeen (Age 57)
Chief People Officer

Ms. Christine Cassiano
Exec. VP, Chief Corp. Affairs & Brand Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.
What is Allogene Therapeutics' stock price forecast for 2023?: 11 analysts have issued twelve-month price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they anticipate the company's share price to reach $16.35 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.
How have ALLO shares performed in 2023?: Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 42.0% and is now trading at $3.65.
View the best growth stocks for 2023 here.
When is Allogene Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ALLO earnings forecast.
How were Allogene Therapeutics' earnings last quarter?: Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.01 million. Allogene Therapeutics had a negative net margin of 184,733.34% and a negative trailing twelve-month return on equity of 54.13%. The business's revenue was down 48.8% on a year-over-year basis. During the same period last year, the company posted ($0.52) EPS.
What ETFs hold Allogene Therapeutics' stock?: ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and
What is David Chang's approval rating as Allogene Therapeutics' CEO?: 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Allogene Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?: (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.
What is Allogene Therapeutics' stock symbol?: Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."
Who are Allogene Therapeutics' major shareholders?: Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (5.06%), BlackRock Inc. (5.04%), JPMorgan Chase & Co. (3.66%), Woodline Partners LP (3.17%), Geode Capital Management LLC (1.09%) and Goldman Sachs Group Inc. (0.89%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends.
How do I buy shares of Allogene Therapeutics?: Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Allogene Therapeutics' stock price today?: One share of ALLO stock can currently be purchased for approximately $3.65.
How much money does Allogene Therapeutics make?: Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $611.85 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.
How many employees does Allogene Therapeutics have?: The company employs 359 workers across the globe.
How can I contact Allogene Therapeutics?: Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial